Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
REXAHN PHARMACEUTICALS, Inc. Add to My Watchlist (AMEX: RNN) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     REXAHN 0.75 +0.06 (+8.70%) 2,551,605
9620 Medical Center Drive
Rockville, MD 20850 US
(240) 268-5300
(240) 268-5310 fax
www.rexahn.com
CEO Dr. Chang Ho Ahn, Ph.D.
Auditor LAZAR LEVINE & FELIX LLP
Exchange Traded AM
ISIN Number US7616401011
CIK Number 1228627
NAICS Code 325412
Business Summary
A clinical stage biopharmaceutical company, which is dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other unmet medical needs.
Number of Employees 14
Share Fundamentals
Market Cap 53.94M
Shares Outstanding 71.92M
Float 46.42M
Short Interest 71.83K
Financial Strength
Revenue (TTM) $75,750
Earnings (TTM) -$6,153,429
Quick Ratio 8.7:1
Current Ratio 9.2:1
Total Debt/Equity 0:1
Profitability
Gross Margin -29.2%
EBITDA Margin N/A
Profit Margin N/A
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs